Heidelberg Pharma AG

General information
Heidelberg Pharma AG
Schriesheimer Straße 101
D-68526 Ladenburg, Bavaria

Contact person: Andreas Pahl, Chief Scientific Officer
Company main phone: +49 (6203) 10090
Company main fax:  +49 (6203) 100919
Website:  www.heidelberg-pharma.com
Year founded:1997
Source of foundation:Independent foundation
No. of employees: Worldwide:  72
Corporate description / mission:
Heidelberg Pharma AG operates as a biopharmaceutical company. The company focuses on development and commercialization of novel cancer therapies. The company offers pharmacology, drug metabolism, pharmacokinetics analysis, and molecular biology in the fields of oncology and inflammatory diseases.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2006
Remarks on ownership / listings
Formerly WILEX AG

The company’s shares will continue to be listed on the Regulated Market of the Frankfurt Stock Exchange’s Prime Standard under their old ISIN, German securities identification code (WKN) and symbol. Its subsidiary Heidelberg Pharma GmbH is now doing business as Heidelberg Pharma Research GmbH.
  • Biotechnology - Therapeutics and Diagnostics
  • Antibodies
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Out-licensing
  • R&D
  • Research on contract basis
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:1
Phase II:3
Phase III:1
Description of products:
CD19-ATAC, etc.
Technology used:
ADC technology
Financing details
Market cap. / valuation:EUR 133.40M
Financing details:
Market capitalization as on 2 March 2021.
Collaborations & Clients
Partnering strategy / collaborations:
Magenta Therapeutics
MabVax, etc,